Clinical study of boron neutron capture therapy (BNCT) for gliomas has progressed rapidly over the past several decades. However, efficacy of BNCT for brain tumors is far from being perfect at present because of the lack of selectivity of the boron carriers and the characteristics of malignant glioma. Moreover, BNCT may have a significant therapeutic effect on refractory pituitary adenomas which have the malignant characters as well as glioma. This paper reviews the current status of BNCT for human liomas and the possibility to treat refractory pituitary adenomas with BNCT.